Multiple Sclerosis Experimental Treatment

Featured Article

British researchers have found that 71 percent of patients with relapsing-remitting multiple sclerosis (MS) who were treated with the experimental drug alemtuzumab in a recent study showed no disease activity after four years. This figure is twice the percentage of patients who achieve remission for this period of time who take the standard treatment Rebif, the scientists say.

Read more

More information on "Multiple Sclerosis Experimental Treatment"

From Our Experts

See more SharePosts »

From Our Sources

More on Multiple Sclerosis »

8 Multiple Sclerosis Treatments and Their Side Effects

Ivbag

Corticosteroids Since 2007, high doses of intravenous corticosteroids such as methylprednisone have been the first-line treatment for the prevention of disability from acute MS attacks. Osteoporosis and reversible short-term memory loss have been...